Literature DB >> 11587999

Reversible airflow obstruction, proliferation of abnormal smooth muscle cells, and impairment of gas exchange as predictors of outcome in lymphangioleiomyomatosis.

A M Taveira-DaSilva1, C Hedin, M P Stylianou, W D Travis, K Matsui, V J Ferrans, J Moss.   

Abstract

Lymphangioleiomyomatosis (LAM) is a rare disease, occurring in women, characterized by cystic degeneration of the lungs, abdominal tumors, and proliferation of abnormal smooth muscle cells. Lung function abnormalities consist of impairment of the diffusion capacity (DL(CO)) and airflow obstruction. The objective of this study was to correlate the functional impairment with histologic measures of disease severity to identify predictors of disease outcome. Lung function of 143 patients and lung biopsies of 74 of these patients were reviewed for evidence of airway disease and scoring of disease severity. A positive response to bronchodilators was associated with more severe airflow obstruction, a predominantly solid pattern of LAM lesions in the lung biopsy, and greater rate of decline in expiratory flow. Airway inflammation, present in 61% of the lung specimens, was not associated with reversible airway obstruction and did not correlate with the severity of airflow obstruction. DL(CO) correlated best with the LAM histologic score (LHS), a demonstrated predictor of outcome. We conclude that reversible airway obstruction is found in LAM patients with accelerated loss of lung function and a predominantly solid pattern of LAM lesions. Impairment of DL(CO) correlates with LHS, a predictor of survival and time to lung transplantation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11587999     DOI: 10.1164/ajrccm.164.6.2102125

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  37 in total

1.  Treatment option(s) for pulmonary lymphangioleiomyomatosis: progress and current challenges.

Authors:  Vera P Krymskaya
Journal:  Am J Respir Cell Mol Biol       Date:  2012-05       Impact factor: 6.914

2.  Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis.

Authors:  Nishant Gupta; Hye-Seung Lee; Lisa R Young; Charlie Strange; Joel Moss; Lianne G Singer; Koh Nakata; Alan F Barker; Jeffrey T Chapman; Mark L Brantly; James M Stocks; Kevin K Brown; Joseph P Lynch; Hilary J Goldberg; Gregory P Downey; Angelo M Taveira-DaSilva; Jeffrey P Krischer; Kenneth Setchell; Bruce C Trapnell; Yoshikazu Inoue; Francis X McCormack
Journal:  Eur Respir J       Date:  2019-04-04       Impact factor: 16.671

3.  The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment.

Authors:  Jay H Ryu; Joel Moss; Gerald J Beck; Jar-Chi Lee; Kevin K Brown; Jeffrey T Chapman; Geraldine A Finlay; Eric J Olson; Stephen J Ruoss; Janet R Maurer; Thomas A Raffin; Hannah H Peavy; Kevin McCarthy; Angelo Taveira-Dasilva; Francis X McCormack; Nilo A Avila; Rosamma M Decastro; Susan S Jacobs; Mario Stylianou; Barry L Fanburg
Journal:  Am J Respir Crit Care Med       Date:  2005-10-06       Impact factor: 21.405

4.  Involvement of lymphatics in lymphangioleiomyomatosis.

Authors:  Connie G Glasgow; Angelo Taveira-DaSilva; Gustavo Pacheco-Rodriguez; Wendy K Steagall; Katsuya Tsukada; Xiong Cai; Souheil El-Chemaly; Joel Moss
Journal:  Lymphat Res Biol       Date:  2009-12       Impact factor: 2.589

Review 5.  Lymphangioleiomyomatosis: what do we know and what are we looking for?

Authors:  S Harari; O Torre; J Moss
Journal:  Eur Respir Rev       Date:  2011-03

6.  The natural history of lymphangioleiomyomatosis: markers of severity, rate of progression and prognosis.

Authors:  Angelo M Taveira-DaSilva; Gustavo Pacheco-Rodriguez; Joel Moss
Journal:  Lymphat Res Biol       Date:  2010-03       Impact factor: 2.589

Review 7.  Pulmonary manifestations in tuberous sclerosis complex.

Authors:  Nishant Gupta; Elizabeth P Henske
Journal:  Am J Med Genet C Semin Med Genet       Date:  2018-07-28       Impact factor: 3.908

8.  Reversible airflow obstruction in lymphangioleiomyomatosis.

Authors:  Angelo M Taveira-DaSilva; Wendy K Steagall; Antoinette Rabel; Olanda Hathaway; Sergio Harari; Roberto Cassandro; Mario Stylianou; Joel Moss
Journal:  Chest       Date:  2009-05-15       Impact factor: 9.410

9.  Pulmonary artery pressure in lymphangioleiomyomatosis: an echocardiographic study.

Authors:  Angelo M Taveira-DaSilva; Olanda M Hathaway; Vandana Sachdev; Yukitaka Shizukuda; Charles W Birdsall; Joel Moss
Journal:  Chest       Date:  2007-09-21       Impact factor: 9.410

Review 10.  Lymphangioleiomyomatosis and tuberous sclerosis complex.

Authors:  Dimitrios Chorianopoulos; Grigoris Stratakos
Journal:  Lung       Date:  2008-04-12       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.